Dabigatran approved in Japan for atrial fibrillation
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim's novel, oral direct thrombin inhibitor dabigatran etexilate has been approved for sale in Japan.It will be launched under the brand name Prazaxa for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF), marking the first approval of a novel oral anticoagulant in the Asia-Pacific region and specifically Japan for nearly 50 years, according to the company.